Ara S. Khachaturian

Ara S. Khachaturian, Ph.D.
Chair Interim President
National Biomedical Research Ethics Council (NBREC)
Executive Vice President of Prevent Alzheimer's & Dementia: Journal of the Alzheimer's Association
Managing Associate, Khachaturian and Associates Inc.
Executive Editor, Alzheimer's & Dementia: Journal of hte Alzheimer's Assocation

Among the roles listed above, Dr. Khachaturian is also the former chief program officer the Lou Ruvo Brain Institute in Las Vegas, Nevada. He has nearly twenty years of experience in the area of epidemiological and clinical research, including specialized experience in population research, and managing state-of-the-art research related to the fields of psychiatric epidemiology, pharmacogenetics and pharmacoepidemiology.

Currently, Dr. Khachaturian is the Executive Vice President of Prevent Alzheimer’s 2020, Inc., a 501(c)(3) tax exempt public charity.  The organization, also known as PAD 2020, will address two important challenges facing efforts to combat Alzheimer’s disease and other disorders affecting memory, movement and mood.  Presently, Dr. Khachaturian is developing an international health aging cohort program that is presently being developed in North America, Europe and the Middle East.  In addition, he also leading an international effort, in partnership with the Alzheimer’s Association, to establish a National Institutional Review Board for neurodegenerative disease that will provide human subject safety protection for many large clinical trials.  As a senior research fellow at the University of Nevada Las Vegas Supercomputing Center, Dr. Khachaturian is also leading an effort jointly based in Las Vegas and Washington, D.C. to use high performance computing in the establishment of a numerical laboratory for biomedical research.  These projects are aimed to accelerate progress in the discovery of new interventions to cure Alzheimer’s and related neurodegenerative diseases.

Dr. Khachaturian also serves as the Executive Editor of the journal Alzheimer’s & Dementia (impact factor 14.483, ranked third out of 191 journals in the category “Clinical Neurology”).  The Journal publishes manuscripts on many topics of Alzheimer’s, neurodegenerative diseases, and healthy brain aging. This interdisciplinary, peer-reviewed journal offers original research articles, perspectives, and reviews from opinion leaders, focusing on the etiology and disease mechanisms in Alzheimer’s and related disorders, lifestyle and genetic risk factors, screening and early detection, prevention and disease-modifying interventions, public policy, health economics, and services research.

Prior to its renaming as the Cleveland Clinic Lou Ruvo Center for Brain Health, Dr. Khachaturian served as the founding chief operation officer. Dr. Khachaturian oversaw the research, financial and administrative operations for the $100 million non-profit brain research institute.  He directed development of many new systems for the start-up institute including patient registration, patient billing, medical records, engineering, finance, physician billing, materials management, communications, and grant compliance.  He developed and administered a $10 million research budget that received both state and federal-level support.  He was responsible for developing long range scientific strategic plans, financial plan, and master construction site plans, in conjunction with Board of Directors, community leaders, and University of Nevada physicians.  At the behest of the Institute’s Chair and Executive Committee of the Board of Directors, he directed the issuance of both a $70 million tax-exempt revenue bond to finance the Institute’s signature Frank Gehry designed clinical research center and $5 million revenue bond to build an associated Wolfgang Puck restaurant.  The Center’s mission remains the advancement of knowledge on the diagnosis, treatment and care of people with degenerative brain diseases.  These include such diseases as Alzheimer’s (AD), Huntington’s (HD), Parkinson’s (PD), and Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig’s) as well as other forms of dementia and other neurodegenerative conditions.

Dr. Khachaturian is a psychiatric epidemiologist trained at the Bloomberg School of Public Health at the Johns Hopkins University (JHU).  Hi